Regulation of tumor angiogenesis by the immune System

Current Angiogenesis

Volumn 1, Issue 2, 2012, Pages 88-97

  Stewart, Keri Schadler ^a   Ryeom, Sandra W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Anti angiogenic therapy; Immune surveillance; Immune system

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; NITRIC OXIDE; SILTUXIMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; COLON CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NEOPLASM; NEUTROPHIL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84880143149     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/2211552811201020088     Document Type: Review

References (85)

1. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation. J Am Soc Nephrol 2006; 17: 581-589.
2. Burnet M. Cancer - A Biological Approach. Br Med J 1957; 1(5023): 841-847.
3. Thomas L. Cellular and Humoral Aspects of the Hypersensitive States. Pediatrics 1959; 24: 773.
4. Stutman O. Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice. Science 1974; 183: 534-536.
5. Schreiber RD, Olson LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science 2011; 331: 1565-1570.
6. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat. Rev Immunol 2006; 6: 836-848.
7. Nishikawa H, Maeda Y, Ishida T, et al. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood 2012; 119(13): 3097-3104.
8. Weiss VL, Lee TH, Song H, et al. Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells. PLoS ONE 2012; 7; e31962.
9. Smyth MJ. Type I interferon and cancer immunoediting. Nat Immunol 2005; 6: 646-648.
10. Ramin L. Eosinophilic Granulocytes and Damage-associated Molecular Pattern Molecules (DAMPs): Role in the Inflammatory Response Within Tumors (Review). J Immunother 2007; 30: 16-28.
11. James ET. Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact. Semin Cancer Biol 2011; 21: 131-138.
12. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222: 350-366.
13. Cipponi A, Wieers G, van Baren N, Coulie P. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 2011; 60: 1153-1160.
14. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci 1998; 95: 7556-7561.
15. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146.
16. MacKie RM, Reid R, Junor B. Fatal Melanoma Transferred in a Donated Kidney 16 Years after Melanoma Surgery. N Engl J Med 2003; 348: 567-568.
17. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907.
18. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leuk Biol 2002; 71: 907-920.
19. Mamessier E, Sylvain A, Bertucci FO, et al. Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2DMediated and DNAM-Mediated NK Cell. Recog Cancer Res 2011; 71: 6621-6632.
20. Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363: 711-723.
21. Lesterhuis WJ, Haanen J, Punt CJA. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011; 10: 591-600.
22. Beatty G, Chiorean E, Fishman MP. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-1616.
23. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med 2011; 365: 725-733.
24. Qian B-Z, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell 2010; 141: 39-51.
25. Pia Nyberg TS, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008; 13: 6537-6553.
26. + Lymphocytes Predict Clinical Outcome in Breast Cancer. J Clin Oncol 2011; 29: 1949-55.
27. Jenkins MR, Griffiths GM. The synapse and cytolytic machinery of cytotoxic T cells. Curr Opin Immunol 2010; 22: 308-313.
28. Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, Yarkoni S. Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. Immunol Cell Biol 2008; 86: 650-658.
29. + T Cells. Cancer Res 2003; 63: 4095-4100.
30. Briesemeister D, Sommermeyer D, Loddenkemper C, et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer 2011; 128: 371-378.
31. Anders K, Buschow C, Herrmann A, et al. Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer. Cancer Cell 2011; 20: 755-767.
32. Beatty GL, Paterson Y. IFN-gamma Can Promote Tumor Evasion of the Immune System In vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen. J Immunol 2000; 165: 5502-5508.
33. + T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation. Cancer Cell 2011; 18: 485-498.
34. al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, Al-Salam S, Bashir G, Chouaib S. Potent anti-tumor activity of systemicallyadministered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin Immunol 2009; 130: 89-97.
35. Penafuerte C, Bautista-Lopez N, Bouchentouf M, Birman E, Forner K, Galipeau J. Novel TGF-b Antagonist Inhibits Tumor Growth and Angiogenesis by Inducing IL-2 Receptor-Driven STAT1 Activation. J Immunol 2011; 186: 6933-6944.
36. Ali G, Boldrini L, Lucchi M, et al. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br J Cancer 2009; 101: 1869-1875.
37. Weiss TW, Simak R, Kaun C, et al. Oncostatin M and IL-6 Induce u-PA and VEGF in Prostate Cancer Cells and Correlate In vivo. Anticancer Res 2011; 31: 3273-3278.
38. Elhawary A, Shouma A, Eldesoky A, Mosaad Y. Clinical relevance of serum vascular endothelial growth factor and Interleukin-6 in patients with colorectal cancer. Saudi J Gastroenterol 2011; 17: 170-173.
39. Liu Q, Li G, Li R, et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neuro-Oncol 2010; 100: 165-176.
40. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clin Cancer Res 2011; 17: 6083-6096.
41. Wani AA, Jafarnejad SM, Zhou J, Li G. Integrin-linked kinase regulates melanoma angiogenesis by activating NF-[kappa]B/interleukin-6 signaling pathway. Oncogene 2011; 30: 2778-2788.
42. Lin L, Hutzen B, Zuo M, et al. Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells. Cancer Res 2010; 70: 2445-2454.
43. van Oosterhout AJ, Motta AC. Th1/Th2 paradigm: not seeing the forest for the trees? Eur Respir J 2005; 25: 591-593.
44. Hunter CA, Yu D, Gee M, et al. Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis. J Immunol 2001: 166; 5878-5881.
45. Rankin EB, Yu D, Jiang J, et al. An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth. Cancer Biol Ther 2003; 2: 685-691.
46. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 2011; 475: 226-230.
47. + Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 2011; 25: 1271-1277.
48. Liu J, Duan Y, Cheng X, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Comm 2011; 407: 348-354.
49. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-2627.
50. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
51. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-355.
52. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896.
53. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ. Tumorassociated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagnos 2011; 11: 91-100.
54. Nonomura N, Takayama H, Nakayama M, et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 2011; 107: 1918-1922.
55. Zhang B, Gao J, Wang J, Rao Z, Wang B, Gao J. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 2010; 28: 1447-1452.
56. Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymph 2011; 52: 46-52.
57. Chun-Chung L, and Huang T-S. Tumor-Associated Macrophage: Its Role in Tumor Angiogenesis. J Cancer Assoc Mol 2006; 2: 135-140.
58. Lin EY, Li J-F, Gnatovskiy L, et al. Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer. Cancer Res 2006; 66: 11238-11246.
59. Kubota Y, Takubo K, Shimizu T, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009; 206: 1089-1102.
60. Joimel U, Gest C, Soria J, et al. Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate. BMC Cancer 2010; 10: 375.
61. Wu H, Xu J-B, He Y-L, et al. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J Surg Oncol 2012. [epub ahead of print]
62. Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30: 83-95.
63. Volin MV, Koch AE. Interleukin-18: A Mediator of Inflammation and Angiogenesis in Rheumatoid Arthritis. J Interferon Cytokine Res 2011; 31: 745-751.
64. Amin MA, Rabquer BJ, Mansfield PJ, et al. Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases. Ann Rheum Dis 2010; 69: 2204-2212.
65. Amin MA, Mansfield PJ, Pakozdi A, et al. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 2007; 56: 1787-1797.
66. Zheng JN, Pei DS, Mao LJ, et al. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Cancer Gene Ther 2009; 17: 28-36.
67. Zheng JN, Pei DS, Sun FH, et al. Potent antitumor efficacy of interleukin-18 delivered by conditionally replicative adenovirus vector in renal cell carcinoma-bearing nude mice via inhibition of angiogenesis. Cancer Biol Ther 2009; 8: 599-606.
68. Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 1999; 13: 2195-2202.
69. Kinouchi MK, Mizoi T, Ishida K, et al. Infiltration of CD14-positive macrophages at the invasive front indicates a favorable prognosis in colorectal cancer patients with lymph node metastasis. Hepatogastroenterology 2011; 58: 352-358.
70. Buddingh EP, Kuijjer ML, Duim RAJ, et al. Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents. Clin Cancer Res 2011; 17: 2110-2119.
71. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90: 222-231.
72. Kuang DM, Zhao Q, Wu Y, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54: 948-955.
73. Waugh DJ, Wilson C. The Interleukin-8 Pathway in Cancer. Clin Cancer Res 2008; 14: 6735-6741.
74. Gong Y, Koh DR. Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model. Cell Tissue Res 2009; 339: 437-448.
75. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory Mediators Stimulate Neutrophil-Directed Angiogenesis. Arch Surg 1999; 134: 1325-1331.
76. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci 2007; 104: 20262-20267.
77. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci 2006; 103: 12493-12498.
78. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88: 577-583.
79. Menon AG, Janssen-van Rhijn CM, Morreau H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004; 84: 493-501.
80. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
81. Melder RJ, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibro blast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992-997.
82. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. Clin Invest 2008; 118: 3367-3377.
83. Hayakawa Y, Takeda K, Yagita H, et al. IFN-gamma mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002; 100: 1728-1733.
84. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009; 9: 675-681.
85. Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 2011; 81: 1183-1191.